|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2001-6-25
|
|
pubmed:abstractText |
This randomized crossover double-blind placebo-controlled study aimed to assess the efficacy of nateglinide (A-4166), a novel phenylalanine-derived insulin secretagogue, in type 2 diabetic subjects while fasting and 5 min before a standard meal.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0149-5992
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1221-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11423506-Blood Glucose,
pubmed-meshheading:11423506-Cross-Over Studies,
pubmed-meshheading:11423506-Cyclohexanes,
pubmed-meshheading:11423506-Diabetes Mellitus, Type 2,
pubmed-meshheading:11423506-Dose-Response Relationship, Drug,
pubmed-meshheading:11423506-Double-Blind Method,
pubmed-meshheading:11423506-Fasting,
pubmed-meshheading:11423506-Female,
pubmed-meshheading:11423506-Hemoglobin A, Glycosylated,
pubmed-meshheading:11423506-Humans,
pubmed-meshheading:11423506-Hypoglycemic Agents,
pubmed-meshheading:11423506-Insulin,
pubmed-meshheading:11423506-Male,
pubmed-meshheading:11423506-Middle Aged,
pubmed-meshheading:11423506-Phenylalanine,
pubmed-meshheading:11423506-Postprandial Period
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
|
|
pubmed:affiliation |
Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
